Non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MS)

Marchesini, G.; Forlani, Gabriele; Natale, S.; Manini, R.; Baraldi, L.; Bianchi, G; Melchionda, Nazario

doi:10.1016/s1590-8658(02)80224-9

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is consistent with a recent report that hepatic FFA delivery from visceral adipose tissue is not so much (less than 20%) in subjects with a visceral fat area of less than 200 cm 2 (Nielsen et al 2004), as our subjects with average visceral fat area of 143 cm 2 . It has been reported that suppression with insulin of lipolysis and gluconeogenesis in the liver is impaired in the patients with fatty liver (Marchesini et al 2001;Sanyal et al 2001;Seppala-Lindroos et al 2002), and impaired suppression of gluconeogenesis with insulin is correlated with liver fat content (Ryysy et al 2000). Recently, a molecular mechanism of liver insulin resistance by fatty liver has been reported, i.e., hepatic fat accumulation stimulates gluconeogenesis and activates PKC-epsilon and JNK1, which may interfere with tyrosine phosphorylation of IRS-1 and IRS-2, and impair the ability of insulin to activate glycogen synthase (Samuel et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and Body Mass Index in Type 2 Diabetic Subjects

Ishii

Yoshioka

Ishida

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

We measured liver fat content by 3-Tesla magnetic resonance spectroscopy (MRS) in 34 non-to mild obese Japanese subjects with type 2 diabetes, who were not complicated with any liver diseases including clinical fatty liver (liver/spleen ratio of computed tomography [CT] < 0.9) and were not being treated with oral hypoglycemic agents, insulin, or lipid-lowering agents, and analyzed the relationship between liver fat content and body composition and plasma metabolite. The liver fat content is significantly correlated with variables relating to obesity (body mass index [BMI], body weight, fat mass, waist to hip ratio, visceral fat area, subcutaneous fat area, and serum triglyceride), insulin resistance (fasting plasma insulin and homeostasis model assessment of insulin resistance [HOMA-IR]), adipocytokines (serum plasminogen activator inhibitor-1 [PAI-1] and leptin), and serum cholinesterase, but not CT liver/spleen ratio, which is correlated only with fasting plasma glucose, BMI, and HOMA-IR. Multiple regression analysis revealed that the liver fat content is independently associated with serum PAI-1 level (p < 0.001) and BMI (p < 0.05), but not visceral fat area. MRS is a more sensitive method for quantifying liver fat content than CT in type 2 diabetic subjects with nonto mild obesity and without clinical fatty liver. type 2 diabetes; fatty liver; magnetic resonance spectroscopy; plasminogen activator inhibitor-1; body mass index

show abstract

Section: Discussionmentioning

confidence: 99%

Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and Body Mass Index in Type 2 Diabetic Subjects

Ishii

Yoshioka

Ishida

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…This strong association is consistent with other studies conducted on different sample sizes and different ethnic groups. (17)(18)(19) Metabolic syndrome is having higher incidence in Asian population. (20) which can be attributed to relative lack of exercises, central obesity and visceral fat deposition.…”

Section: Discussionmentioning

confidence: 99%

Sonographically Diagnosed Non-Alcoholic Fatty Liver as a Predictor of Metabolic Syndrome

Yadav¹,

Dhruw²,

Shekhawatia³

et al. 2016

jemds

View full text Add to dashboard Cite

CONTEXTNon-alcoholic fatty liver disease (NAFLD) is the most common liver disease, since its prevalence is estimated to be 20-30% in general population of Western countries. Incidence of NAFLD in Indian population is on rise and its exact prevalence is not known. It was thought to be a benign condition, but is now increasingly recognized as a major cause of liver-related morbidity and mortality. Studies have proven that NAFLD may progress to cirrhosis, liver failure and hepatocellular carcinoma, in addition it has been shown that NAFLD is strongly associated to the features of Metabolic Syndrome (MetS). AIMS AND OBJECTIVESTo evaluate the association of sonographically diagnosed nonalcoholic fatty liver with metabolic syndrome and to estimate prevalence of nonalcoholic fatty liver in our population coming for general health check-up. METHODWe recruited 556 subjects, who visited for annual general health checkup at our institute. Based on exclusion criteria 148 subjects were excluded from the study and data from the remaining 408 subjects were included in the final statistical analysis. Characteristic ultrasound features such as increased hepatic echogenicity with attenuation of ultrasound beam and poor visibility of diaphragm and intrahepatic vessel borders were used to diagnose hepatic steatosis. RESULTOut of total 408 subjects who met with our inclusion criterias, 144 were diagnosed as having NAFLD (35.2%) on sonography examination. Mean age of subjects in NAFLD group was 49.54 years; 79% of subjects in NAFLD group in our study had BMI >25, out of which 28.47% were morbidly obese. Tobacco use and lack of physical activity was observed to be more prevalent in NAFLD group. Out of total 144 subjects with NAFLD 43.75% were having metabolic syndrome. This association was statistically extremely significant (P value <0.0001). Components of metabolic syndrome increased waist circumference, hypertension, impaired blood glucose level, low HDL cholesterol and high triglyceride level were more frequently observed in NAFLD group. CONCLUSIONIssue whether or not NAFLD should be included as one of the components of the MetS is still in existence; however, it can be concluded that NAFLD is an important independent risk factor for prediction of MetS. The observations of our study might be helpful to support the clinical guideline and early intervention strategy for the NAFLD patients before being diagnosed as MetS.

show abstract

“…Hence, in the near future, we may anticipate a major increase of young adults with the stigmata of the metabolic syndrome (MetS), and of the related non-alcoholic fatty liver disease (NAFLD), that may lead to non-alcoholic steatohepatitis (NASH) (12,13).…”

Section: Impact Of Childhood Overweight and Obesity On Healthmentioning

confidence: 99%

Pediatric Nonalcoholic Fatty Liver Disease

Goran¹

2016

Childhood Obesity

View full text Add to dashboard Cite

Summary:The rapidly increasing prevalence of childhood obesity and its associated co-morbidities such as hypertriglyceridemia, hyper-insulinemia, hypertension, early atherosclerosis, metabolic syndrome, and non-alcoholic fatty liver disease are major public health concerns in many countries. Therefore the trends in child and adolescent obesity should be closely monitored over time, as in the near future, we may anticipate a major increase of young adults with the stigmata of the metabolic syndrome, and of the related non-alcoholic fatty liver disease (NAFLD), that may lead to non-alcoholic steatohepatitis.

show abstract

Non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MS)

Cited by 10 publications

References 0 publications

Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and Body Mass Index in Type 2 Diabetic Subjects

Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and Body Mass Index in Type 2 Diabetic Subjects

Sonographically Diagnosed Non-Alcoholic Fatty Liver as a Predictor of Metabolic Syndrome

Pediatric Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About